Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-493 coformulated with ABT-530 · 1 trial · 4 indications
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of active study drug.
| Arm | Type | Description |
|---|---|---|
| ABT-493/ABT-530 for 8 weeks | EXPERIMENTAL | HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks |
| ABT-493/ABT-530 for 12 weeks | EXPERIMENTAL | HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks |
| Name | Type | Description |
|---|---|---|
| ABT-493 coformulated with ABT-530 | DRUG | Tablet |
Inclusion Criteria: 1. Male or female, at least 18 years of age at time of Screening. 2. Screening laboratory result indicating Hepatitis C virus (HCV) genotype (GT)1-, 2-, 3-, 4-, 5-, or 6-infection. 3. Subject has positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid (RNA) viral load gr...
ABT-493 coformulated with ABT-530 is an investigational small molecule combination being developed for the treatment of Hepatitis C Virus (HCV) infection. It is studied in adults with chronic HCV genotype 1-6 infection, including those coinfected with HIV-1 and those with compensated cirrhosis or without cirrhosis.
ABT-493 coformulated with ABT-530 is being developed by AbbVie Inc. (NYSE: ABBV). The company is conducting clinical trials to evaluate the efficacy and safety of this experimental drug combination in patients with chronic Hepatitis C Virus infection.
ABT-493 coformulated with ABT-530 is in Phase 3 clinical development. It is an investigational drug combination, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
ABT-493 coformulated with ABT-530 was studied in a Phase 3 clinical trial with the identifier NCT02738138, known as EXPEDITION-2. This completed trial evaluated the efficacy and safety of the drug combination in 153 adults with chronic Hepatitis C Virus genotype 1-6 infection and HIV-1 coinfection.
ABT-493 and ABT-530 are the investigational code names for the components of this drug combination. The trial data provided does not include alternative names, so it is not specified whether these correspond to glecaprevir and pibrentasvir or other approved names.